MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/817,454
Filing Date	04/01/2004
First Named Inventor	David Alan Campbell
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	063391-1802

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
JR	A1	Clontech Catalog: Innovative Tools to Accelerate Discovery. 6-Carboxyfluorescein-ON™ phosphoramidite user manual. PT-3354-1 (PR95959), Published May 3, 1999.	
JR	A2	Madoyan et al., "Affinity labeling of tryptophanyl-tRNA synthetase with mesitoyl-amp." FEBS Letters, 123: 156-160, January 1981.	
JR	A3	Manabe et al., Preparation of glycosylated amino acid derivatives for glycoprotein synthesis by in vitro translation system." Bioorganic & Medicinal Chemistry, 10:573-581, 2002	
JR	A4	International Search Report for PCT Application No. PCT/US2004/10075	

Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete If Known	
Application Number	10/817,454
Filing Date	04/01/2004
First Named Inventor	David Alan Campbell
Group Art Unit	
Examiner Name	
Attorney Docket Number	063391-1802

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JR	A1	4,415,655		De Castro et al.	11-15-1983	
	A2	4,481,094		Fernandez de Castro et al.	11-06-1984	
	A3	4,865,707		Karger et al.	09-12-1989	
	A4	4,946,794		Berube	08-07-1990	
	A5	5,215,970		Datema et al.	06-01-1993	
	A6	6,008,373		Waggoner et al.	12-28-1999	
	A7	6,043,060		Imanishi	03-28-2000	
JR	A8	6,255,292		Liang	07-03-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JR	A9	WO	00/011208		University of Washington	03-02-2000		
JR	A10	WO	01/77668		The Scripps Research Institute	10-18-2001		
JR	A11	WO	01/77684		The Scripps Research Institute	10-18-2001		
JR	A12	WO	03/079014		Pharmacia Groningen BV	01-30-2003		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
JR	A13	Bergseid et al., Small molecule-based chemical affinity system for the purification of proteins. Biotechniques (2000) 29(5):1126-1133	
JR	A14	Bishop et al., Magic bullets for protein kinases. Trends Cell Biol (2001) 11(4):167-172	

Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet | 2 | of | 4

Complete if Known	
Application Number	10/817,454
Filing Date	04/01/2004
First Named Inventor	David Alan Campbell
Group Art Unit	
Examiner Name	
Attorney Docket Number	063391-1802

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
JR	A15	Clauser, et al., Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc. Natl. Acad. Sci. USA (1995) 92:5072-76	
JR	A16	Daniel, SM et al., FastTag™ Nucleic Acid Labeling System: A Versatile Method for Incorporating Haptens, Fluorochromes and Affinity Ligands into DNA, RNA and Oligonucleotides. Biotechniques (1998) 24(3), 484-489	
JR	A17	De Leenheer, et al., Applications of isotope dilution-mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology. Mass Spectrom. Rev. (1992) 11:249-307	
JR	A18	Deutscher (ed.), Methods in Enzymology, (1990) vol. 182, pp. 147-238, chapter 12 by Cull and McHenry entitled "Preparation of extracts from Prokaryotes."	
JR	A19	Eisen et al., Cluster analysis and display of genome-wide expression patterns. *Proc. Natl. Acad. Sci. USA* (1998) 95:14863-14868	
JR	A20	Eng. et al. An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database. J. Am. Soc. Mass Spectrom. (1994) 5:976-989	
JR	A21	Gibson et al., Nonpeptidic $\alpha_v\beta_3$ Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Agnew. Chem. Int. Ed. (2001) 40: 165-169.	
JR	A22	Gottschling et al., Cellular Solid-Phase Binding Assay and Mass Spectrometry for Screening of $\alpha 4\beta 7$ Integrin Antagonists. Bioorg. And Medicinal Chem. Lett. (2001) 11: 2997	
JR	A23	Gygi et al., Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era. Mol. Cell. Biol. (1999) 19:1720-1730	
JR	A24	Gygi, et al., Correlation between Protein and mRNA Abundance in Yeast. Mol. And Cell. Biol. (1999) 20:310-319	

Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/817,454
				Filing Date	04/01/2004
				First Named Inventor	David Alan Campbell
				Group Art Unit	
(use as many sheets as necessary)				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	063391-1802

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
JR	A25	Hanks and Hunter, "The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification." FASEB J. (1995) 9(8):576-596	
JR	A26	Kidd *et al.*, Profiling Serine Hydrolast Activities in Complex Proteomes. *Biochemistry* (2001) 40: 4005-15	
JR	A27	Kolb *et al.*, Click Chemistry: Diverse Chemical Function from a Few Good Reactions. *Agnew Chem. Int. Ed. Engl.* (2001) 40: 2004-21	
JR	A28	Laemmli, Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. *Nature* (1970) 227:680-685	
JR	A29	Lemieux et al. A Fluorogenic Dye Activated by the Staudinger Ligation. J. Am. Chem. Soc. (2003) 125: 4708-4709	
JR	A30	Leon et al., Evaluation of Resins for On-Bead Screening: A Study of Papain and Chymotrypsin Specificity Using Pega-Bound Combinatorial Peptide Libraries. Bioorg. Med. Chem. Lett. (1998) 8: 2997	
JR	A31	Link, et al., Identifying the major proteome components of *Haemophilus influenzae* type-strain NCTC 8143. Electrophoresis (1997) 18:1314-34	
JR	A32	Mann and Wilm, Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags. Anal. Chem. (1994) 66:4390-99	

Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	10/817,454
				Filing Date	04/01/2004
				First Named Inventor	David Alan Campbell
(use as many sheets as necessary)				Group Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	063391-1802

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
JR	A33	Orain and Bradley, Solid phase synthesis of trypanothione reductase inhibitors-towards single bead screening. Tetrahedron Lett. (2001) 42: 515-518	
JR	A34	Papanikos et al., α–Ketocarbonyl Peptides: A General Approach to Reactive Resin-Bound Intermediates in the Synthesis of Peptide Isosteres for Protease Inhibitor Screening on Solid Support. J. Am. Chem. Soc. (2001) 123: 2176 2181	
JR	A35	Porco, Organic Synthesis Using Chemical Tags: The "Third Leg" of Parallel Synthesis. JA Comb. Chem. High Throughput Screening (2000) 3(2) 93-102	
JR	A36	Ross et al., Systematic variation in gene expression patters in human cancer cell lines. *Nat. Genet. (2000)*24:227-235	
JR	A37	Seo *et al.*, Click Chemistry to Construct Fluorescent Oligonucleotides for DNA Sequencing. *J. Org. Chem.* (2003) 68: 609-612	
JR	A38	Smith and Bradley, Comparison of Resin and Solution Screening of Methodologies in Combinatorial Chemistry and the Identification of a 100nM Inhibitor of Trypanothione Reductase. J. Comb. Med. (1999) 1: 326-332.	

Examiner Signature	/Jezia Riley/	Date Considered	02/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.